Welcome to the RNA CTx Summit
While CTx is rapidly becoming the 3rd pillar of medicine, and RNA engineering promises improved safety, functionality and scalability profiles to accelerate to approval. Now is the time to gather this burgeoning community together to overcome the specific challenges associated with RNA CTx development to accelerate these promising therapies through the value chain.
Experts will unite over three days, including two deep-dive workshops, dedicated Q&As, interactive panel discussions and highly appraised networking opportunities to meet and learn from the pioneers taking this field forward.
Tackle the top 5 priorities in the field, including:
Progress cell-specific RNA delivery methods for efficient CTx transfection and prevent off-target toxicity with BioNTech, Gamida Cell and Targovax
Explore RNA modifications to drive durable therapeutic responses with transient RNA effects with Intellia Therapeutics, Editas and SQZ Biotech
Overcome immunogenicity and elucidate the pathway from bench to benchside to accelerate to approval with Cartesian, Lupagen and Sanofi
Enhance analytical and process development to optimize purity levels and meet quality attributes to satisfy regulators with Tidal (a Sanofi Company), Sana Biotechnologies and Cartesian Therapeutics
Network with cell & RNA therapy developers & investors to understand the current landscape, navigate IP hurdles & showcase your platforms with Exacis, Rothwell Figg and Qiming Venture Partners
"It was a great opportunity to hear all the new insights in the field, for networking, and understanding new technology innovation"
Peter Dalama, Biologics, Process Development Manager, EVA Pharma
